ReviewZeitschrift fur Rheumatologie2026
[Polymyalgia rheumatica].
Review in Zeitschrift fur Rheumatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polymyalgia rheumatica (PMR) is a common inflammatory rheumatic disease of older adults, characterized by bilateral pain in the shoulder and pelvic girdles, morning stiffness, and systemic signs of inflammation. Despite its high prevalence, PMR remains a clinical challenge due to diagnostic uncertainty and a broad spectrum of differential diagnoses. Furthermore, disease management is complicated by the overlap with giant cell arteritis and the frequently required long-term glucocorticoid therapy due to recurrent relapses, which in turn is associated with an increased risk of treatment-related adverse effects. Early confirmation of the diagnosis, structured patient stratification, and the integration of individual risk factors into therapeutic decision-making are essential for the optimal management of patients with PMR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.